Cancer
Conditions
Keywords
melanoma, dabrafenib, BRAF V600, rabeprazole, rifampin
Brief summary
The study is being conducted to evaluate the effect of rifampin (a strong CYP3A4 inducer) and rabeprazole (a pH elevating agent) on the PK of dabrafenib (a CYP3A4/CYP2C8 substrate). The study will be conducted in subjects with BRAF V600 mutation-positive tumors. Data collected from this study will be used to inform recommendations regarding use of concomitant medications with dabrafenib and future clinical pharmacologic evaluation of dabrafenib.
Interventions
DRUGDabrafenib 150 mg twice a day (BID)
Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
DRUGRabeprazole 40 mg once daily (OD)
Rabeprazole dosed at 40mg each morning on Days 16 to 19
DRUGRifampin 600 mg OD
Rifampin dosed at 600mg each morning on Days 20 to 29
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female at least 18 years of age at the time of signing the informed consent form. * Provided signed written informed consent. * Capable of compliance with the requirements and restrictions listed in the consent form. * Body weight \>=45 kilogram (kg) and a body mass index (BMI) \>=19 Kilogram per meter squared (kg/m\^2) and \<40 kg/m\^2 (inclusive). * Able to swallow and retain oral medication. * BRAF V600 mutation-positive tumor as confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory or equivalent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate baseline organ function defined in study protocol. * Women of child-bearing potential must be willing to practice acceptable methods of birth control. Additionally, women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study medication.
Exclusion criteria
* History of another malignancy with exceptions below, or any malignancy with confirmed activating RAS mutation. Exception: (a) Subjects who have been successfully treated and are disease-free for 5 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission, or (e) indolent prostate cancer (definition: clinical stage T1 or T2a, Gleason score \<=6, and PSA \<10 nanogram per milliliter \[ng/mL\]) requiring no or only anti-hormonal therapy, are eligible. * Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of dabrafenib. * Unresolved toxicity greater than Grade 2 from previous anti-cancer therapy except alopecia. * Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures. * Current use of therapeutic warfarin. * Any prohibited medication(s) or herbal preparation as described in study protocol or requires any of these medications during the study. * Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to dabrafenib, rabeprazole and rifampin, or excipients that contraindicates their participation. * Pregnant or nursing females. * A history or evidence of cardiovascular risk including any of the following: a QT interval corrected for heart rate using the Bazett's formula (QTcB) \>=480 milliseconds (msec); a history or evidence of current clinically significant uncontrolled arrhythmias; a history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; a history or evidence of current \>=Class II congestive heart failure (CHF) as defined by the New York Heart Association (NYHA) guidelines; Abnormal cardiac valve morphology (\>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities \[i.e., mild regurgitation/stenosis\] can be entered on study). Subjects with moderate valvular thickening should not be entered on study. * Presence of active gastrointestinal (GI) disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor. * A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection. * Subjects with brain metastases are excluded if their brain metastases are: Symptomatic, Treated (surgery, radiation therapy) but not clinically and radiographically stable one month after local therapy, or asymptomatic and untreated but \>1 centimeter (cm) in the longest dimension. Subjects with small (\<=1 cm in the longest dimension), asymptomatic brain metastases that do not need immediate local therapy can be enrolled. Subjects on a stable dose of corticosteroids for \>1 month, or those who have been off corticosteroids for at least 2 weeks can be enrolled. Subjects must also be off of enzyme-inducing anticonvulsants for more than 4 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameters including: maximum observed concentration (Cmax) |
| PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameters including: time to Cmax (tmax) |
| PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameters including: area under the concentration-time curve over the dosing interval (AUC\[0-tau\]) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameter (tmax), after administration of Dabrafenib co-administered with rabeprazole or rifampin |
| Ratio of metabolite to Dabrafenib | Day 15, 19 and Day 29 | Blood samples will be collected for AUC(0 tau) to estimate ratio of Dabrafenib metabolites to parent Dabrafenib co-administered with rabeprazole or rifampin |
| Safety and tolerability assessment to measure vital signs | Day 15, 19 and Day 29 | Safety and tolerability assessment for vital signs including systolic and diastolic blood pressure, temperature, and pulse rate for dabrafenib in combination with rabeprazole or rifampin |
| Safety and tolerability assessment for 12-lead ECG | From Screening up to follow up visit within 7-10 days of the last dose of study medication | A single 12-lead ECG will be obtained to assess safety and tolerability of dabrafenib in combination with rabeprazole or rifampin |
| PK assessment of Dabrafenib co administered with rabeprazole or rifampin | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameters including: Pre-dose concentration (Ctau) after administration of Dabrafenib co-administered with rabeprazole or rifampin |
| Safety and tolerability assessment of dabrafenib in combination with rabeprazole or rifampin | From Screening up to follow up visit within 7-10 days of the last dose of study medication | Safety and tolerability assessment includes adverse events (AEs) and serious adverse events (SAEs) |
| Concentrations of Rabeprazole in the presence of Dabrafenib | Predose, 1, 2, 3 and 12 hours postdose on Day 19 | Blood sample will be collected to measure concentration of Rabeprazole in the presence of Dabrafenib |
| Concentrations of Rifampin in the presence of Dabrafenib | Predose, 1, 2, 3 and 12 hours postdose on Day 29 | Blood sample will be collected to measure concentration of Rifampin in the presence of Dabrafenib |
| Safety and tolerability assessment for laboratory tests | From Screening up to follow up visit within 7-10 days of the last dose of study medication | Safety and tolerability assessment for clinical laboratory tests including hematology, clinical chemistry and other tests for dabrafenib in combination with rabeprazole or rifampin |
| PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameter (AUC\[0-tau\]) after administration of Dabrafenib co-administered with rabeprazole or rifampin |
| PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib | Day 15, 19 and Day 29 | Blood samples will be collected to assess PK parameters including: Cmax and Ctau, after administration of Dabrafenib co-administered with rabeprazole or rifampin |
Countries
Australia, United Kingdom, United States
Outcome results
None listed